Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230905 | 0.79 | MEN1 (0.50) | ATMPTGS2PTGS1ALDH1A1MAPT | |
| SCHEMBL3223168 | 0.78 | MAPT (0.56) | ATMPTGS2PTGS1ALDH1A1MAPT | |
| SCHEMBL10330357 | 0.78 | HPGD (0.56) | ALOX5ALDH1A1MAPTGAAHTT | |
| SCHEMBL3210223 | 0.76 | PTGS2 (0.40) | ATMALOX5PTGS2PTGS1ALDH1A1 | |
| SCHEMBL7912386 | 0.75 | MEN1 (0.52) | ALDH1A1MAPTTSHRGAACYP1A2 | |
| SCHEMBL758323 | 0.75 | ATM (0.66) | ATMPTGS2TSHRGAAL3MBTL1 | |
| SCHEMBL24458113 | 0.72 | NPC1 (0.65) | ATMPTGS2ALDH1A1MAPTGAA | |
| SCHEMBL15624757 | 0.69 | ATM (0.59) | ATMPTGS2TSHRGAAL3MBTL1 | |
| SCHEMBL27854375 | 0.69 | ALDH1A1 (0.54) | ALDH1A1MAPTTSHRMAPK1GAA | |
| SCHEMBL2602390 | 0.68 | PTGS2 (0.56) | ALOX5PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | BIOMARIN IGA LIMITED | 2010-07-01 | — | — | US | claimed |
| US-20120149741-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2012-06-14 | — | — | US | disclosed |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | BIOMARIN IGA LIMITED | 2010-07-01 | — | — | US | disclosed |
| EP-2176230-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-04-21 | — | — | EP | disclosed |
| EP-2170325-A2 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2010-04-07 | — | — | EP | disclosed |
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2010-02-25 | — | — | US | disclosed |
| WO-2009021747-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009019505-A2 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1986643-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091107-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SMN1; SMN2, CPT1B, GYS1 | ATM 1568/4885ALOX5 4110/4885PTGS2 4079/4885 |
| US-20120149741-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SMN1; SMN2, ACVR2B, CPT1B | ATM 2063/4885ALOX5 3969/4885PTGS2 3442/4885 |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | CPT1B, PYGM, MTPN | ATM 1905/4885ALOX5 2341/4885PTGS2 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.